Emergency: 911 Crisis: call or text 988 PA DDAP: 1-800-662-4357 PA 211: 2-1-1
24/7 Placement Advisors — Call (215) 792-4574
Philadelphia — Available 24/7

Inpatient Drug Rehab in Philadelphia

We connect Philadelphia residents with licensed inpatient treatment programs. Insurance verified free — most PPO plans cover the full cost of rehab.

  • Insurance Verified Free
  • Available 24/7
  • PPO Plans Accepted
  • Same-Day Placement

Philadelphia recorded 1,045 overdose deaths in 2024 — a 20% decline from the prior year's peak, yet still among the highest rates of any large U.S. city. Source: Philadelphia Health Dept / billypenn.com

Philadelphia Inpatient Drug Rehab — Available 24/7

Anchor Point connects Philadelphia-area residents and families with licensed inpatient addiction treatment. Free insurance verification, 24/7 placement, most PPO plans accepted.

🏥

Inpatient Rehab

24/7 medically supervised residential treatment — the highest level of care for fentanyl, heroin, alcohol, and poly-drug dependence.

💊

Medical Detox

Philadelphia's drug supply now includes fentanyl, xylazine, and medetomidine. Safe medical detox is critical — home detox is dangerous.

🧠

Dual Diagnosis

Addiction rarely travels alone. Licensed programs treat co-occurring depression, anxiety, PTSD, and trauma alongside substance use disorder.

📋

Insurance Verification

PA Act 106 requires most group plans to cover SUD treatment. We verify your benefits in minutes — free, confidential, no obligation.

Ready to Talk? Call (215) 792-4574 — Available 24/7.

Free insurance verification in minutes. Most PPO plans cover inpatient rehab. Confidential, no obligation.

(215) 792-4574

Philadelphia's Overdose Crisis — 2024 Data

Source: Philadelphia Department of Public Health

1,045
Overdose Deaths
Philadelphia 2024
↓20%
Decline from 2023
Second consecutive drop
83%
Involved Fentanyl
2023 deaths
38%
Involved Xylazine
2023 deaths
63%
Involved Cocaine
2023 deaths
69%
Occurred at Home
Fatal ODs
⚠️ NEW: Medetomidine Alert

As of January 2025, medetomidine — 200× more potent than xylazine — has been detected in 87% of Philadelphia drug samples. It causes severe withdrawal symptoms that naloxone cannot reverse. Medical detox is now more important than ever.

Call (215) 792-4574 — Placement Advisors Available 24/7

Most PPO plans cover inpatient rehab under PA Act 106. Free, confidential insurance verification in minutes.

(215) 792-4574

What Is Inpatient Drug Rehab?

Inpatient drug rehab — also called residential treatment — is a 24/7 live-in program that provides medical supervision, individual therapy, group counseling, and structured support for people with moderate-to-severe substance use disorder. Unlike outpatient treatment, patients stay at a licensed facility during the program, removing them from the environment and triggers that contribute to continued use. For Philadelphians dealing with fentanyl, xylazine, medetomidine, or poly-drug dependence, inpatient care is typically the safest and most effective starting point.

Why Philadelphia Residents Need Specialized Inpatient Care

Philadelphia's drug supply is unlike anywhere else in the country. Fentanyl is present in 83% of overdose deaths — but it's now commonly combined with xylazine ('tranq'), which causes severe skin wounds that standard addiction treatment doesn't address, and medetomidine, a veterinary anesthetic detected in 87% of Philadelphia drug samples as of January 2025. This poly-drug reality means that standard detox protocols designed for heroin or alcohol aren't sufficient. Inpatient programs that understand Philadelphia's specific drug landscape — and can manage xylazine wounds, medetomidine withdrawal, and fentanyl dependence simultaneously — provide a level of care that outpatient settings simply can't match.

Does Insurance Cover Inpatient Rehab in Philadelphia?

In most cases, yes. Pennsylvania's Act 106 requires group health plans to cover substance use disorder treatment, including inpatient care. Federal parity law (MHPAEA) further requires that insurers not apply stricter coverage limits to addiction treatment than they would to medical or surgical care. Most commercial PPO plans — including Aetna, Cigna, Independence Blue Cross, and others common in the Philadelphia area — cover the majority of inpatient rehab costs. Calling (215) 792-4574 connects you with a placement advisor who can verify your benefits and estimate your out-of-pocket cost before you commit to anything.

1,045
Philadelphia OD Deaths
2024
$56,708
Avg PA Rehab Cost
Insurance covers most
24/7
Placement Advisors
Call anytime
Act 106
PA Insurance Mandate
SUD coverage required

Frequently Asked Questions About Philadelphia Inpatient Rehab

How long does inpatient drug rehab take in Philadelphia?

Most inpatient programs run 30, 60, or 90 days. A 30-day program is the minimum clinically recommended stay. For Philadelphia residents dealing with fentanyl and poly-drug dependence — particularly where xylazine or medetomidine is involved — 60–90 days is often recommended, as these substances require extended stabilization and wound management beyond what a 30-day stay covers.

Does insurance pay for drug rehab in Philadelphia?

Most commercial PPO plans pay for the majority of inpatient rehab costs. Pennsylvania's Act 106 law mandates that group health plans cover substance use disorder treatment. Federal parity law (MHPAEA) prevents insurers from applying stricter rules to addiction care than other medical care. Call (215) 792-4574 for a free insurance verification — most people are surprised by how much is covered.

What is xylazine and why does it matter for rehab?

Xylazine — known as 'tranq' on the street — is a veterinary sedative mixed into the Philadelphia drug supply. It was detected in 38% of all overdose deaths in 2023. Naloxone does not reverse xylazine. It also causes severe, slow-healing skin wounds that require specialized wound care during treatment. Inpatient programs in Philadelphia have adapted protocols to treat xylazine-involved dependence — this is why specialized local placement matters.

What is medetomidine and is it in Philadelphia's drug supply?

Medetomidine is a veterinary anesthetic that has replaced xylazine as the dominant adulterant in Philadelphia's drug supply. As of January 2025, it was detected in 87% of drug samples — and is 200 times more potent than xylazine. It causes a more severe withdrawal syndrome, including intractable vomiting, tremors, and tachycardia. Medical detox under clinical supervision is critical for anyone using street drugs in Philadelphia.

How do I get into rehab quickly in Philadelphia?

Call (215) 792-4574 — placement advisors are available 24/7. They will verify your insurance on the call, identify available inpatient programs that match your clinical needs, and help arrange admission as quickly as same day in many cases. You do not need a referral from a doctor. You do not need to have everything figured out. You just need to call.

Call Now